Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Eli Lilly LLY -1.05% ...

Verve's top drug, Verve-102, is designed to target a gene called PCSK9, which is associated with heart health and cholesterol levels.

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

The question is Wall Street’s version of white noise.When you’re stumped or don’t have the time or simply don’t want to make ...

Eli Lilly's stock recently took a hit, leaving investors scrambling like pharmacists out of espresso. The company’s ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Wealth Enhancement Advisory Services LLC boosted its stake in Eli Lilly by grabbing an extra 15,393 shares, totaling a ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

The stock has dropped to its lowest level in four years compared to the U.S. energy index, which has reversed the gains from ...

Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.

U.S. stocks are holding nearly in place as Wall Street waits to hear where the Federal Reserve may be taking interest rates. The S&P 500 was little changed early Wednesday.

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...